Press Releases

Date Title and Summary View
Toggle Summary Aquinox Pharmaceuticals to Announce Second Quarter Financial Results and Host Conference Call on August 11, 2014
VANCOUVER, British Columbia, Aug. 5, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, will report its second quarter 2014 financial results
View HTML
Toggle Summary Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase 2 Trials of AQX-1125, Including Acceptance of U.S. IND
VANCOUVER, British Columbia , June 2, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced expansion of its ongoing Phase 2 clinical trials
View HTML
Toggle Summary Aquinox Pharmaceuticals to Present at Upcoming Investor Conferences
VANCOUVER, British Columbia, May 21, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq:AQXP), a clinical stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced that David Main, Aquinox's Chief
View HTML
Toggle Summary Aquinox Pharmaceuticals Announces Presentation on FLAGSHIP Study at the 2014 American Thoracic Society International Conference
VANCOUVER, British Columbia, May 14, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq:AQXP), a clinical stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced that the company will present a "study
View HTML
Toggle Summary Aquinox Pharmaceuticals Announces First Quarter 2014 Financial Results
VANCOUVER, British Columbia, May 13, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today provided a corporate update and reported
View HTML
Toggle Summary Aquinox Pharmaceuticals Announces Closing of Initial Public Offering
Full Exercise of Underwriters' Option to Purchase Additional Shares for Aggregate Offering Price of $53.1 Million
View HTML
Toggle Summary Aquinox Pharmaceuticals Prices Initial Public Offering
VANCOUVER, British Columbia, March 7, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $11.00 per share for an aggregate offering of $46.2 million, before
View HTML
Toggle Summary Aquinox Pharmaceuticals commences Phase 2 clinical trial of AQX-1125 in Chronic Obstructive Pulmonary Disease
Oral once daily therapy being studied for population of highest unmet need and leading cause of urgent hospitalizations
View HTML
Toggle Summary Aquinox Pharmaceuticals commences Phase II clinical trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis
Once a day oral therapy being studied for condition that predominantly affects women and has major health consequences
View HTML
Toggle Summary Aquinox Pharmaceuticals Completes US $18 Million Series C Financing
Positive Phase IIa results attract additional funds and new syndicate member to advance clinical development and strengthen management team
View HTML